<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03658434</url>
  </required_header>
  <id_info>
    <org_study_id>PRADO</org_study_id>
    <nct_id>NCT03658434</nct_id>
  </id_info>
  <brief_title>Palliative Radiotherapy to Dominant Symptomatic Lesion in Patients With Hormone Refractory Prostate Cancer</brief_title>
  <acronym>PRADO</acronym>
  <official_title>Palliative Radiotherapy to Dominant Symptomatic Lesion in Patients With Hormone Refractory Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zealand University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Schleswig-Holstein</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Zealand University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the present feasibility study of a new short palliative radiotherapy regime that
      apply to patients with metastatic hormone refractory prostate cancer (HRPC) presenting with a
      dominating debilitating symptom. Diffusion weighted magnetic resonance imaging (DWI) will
      apply to identify both the lesion and the most aggressive part of the lesion. The symptomatic
      lesions will be treated with a dose of 4 x 5 Gy, while for the most aggressive part of the
      lesion the dose will be escalated to 4 x 7 Gy using a simultaneous integrated boost (SIB)
      technique.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Please refer to uploaded Study Protocol
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2018</start_date>
  <completion_date type="Anticipated">August 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Feasibility study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of study participants that complete the study</measure>
    <time_frame>6 months</time_frame>
    <description>Proportion of study participants that complete radiotherapy with ≥ 90% of prescribed dose</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response in dominating symptom score (short form McGill pain Questionnaire)</measure>
    <time_frame>Baseline, 1,3 and 6 months after radiotherapy</time_frame>
    <description>Patient score symptom/pain using the short form McGill pain Questionnaire version 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute radiation toxicity score using CTCAE</measure>
    <time_frame>Baseline, 1,3 and 6 months after radiotherapy</time_frame>
    <description>Doctor score acute radiation toxicity using the CTCAE version 4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life score using EORTC QLQ-C30</measure>
    <time_frame>Baseline and 6 months after radiotherapy</time_frame>
    <description>Patient fill out EORTC quality of life Questionnaire form C30</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">34</enrollment>
  <condition>Hormone-refractory Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>feasibilty</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Palliative Radiotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Palliative radiotherapy</intervention_name>
    <description>Palliative Radiotherapy to Dominant Symptomatic Lesion in Patients With Hormone Refractory Prostate Cancer</description>
    <arm_group_label>feasibilty</arm_group_label>
    <other_name>PRADO</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with hormone refractory biopsy proven prostate cancer

          2. Presenting with a dominating debilitating symptom

          3. Expected median survival of 12 months

          4. Focal irradiation of lesion is feasible

          5. Systemic therapy according to guidelines

          6. age ≥18 years

          7. Legal capacity, able to understand consequences of the trial

          8. Written informed consent

        Exclusion Criteria:

          1. Relevant comorbidity (limiting radiotherapy according to protocol)

          2. Prior radiotherapy limitations to administer radiotherapy according to protocol

          3. No large metal implants in vicinity of lesion

          4. Department dose constraints for normal tissue can't be met

          5. Large bony lesions with extensive osseous destruction

          6. Patients symptoms do not correlate with MR findings
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jesper H Carl, Phd</last_name>
    <role>Study Chair</role>
    <affiliation>Oncology, Zealand University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Redas Trepiakas, MD</last_name>
    <phone>+45 56 51 3231</phone>
    <email>rtr@regionsjaelland.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>K F E</last_name>
    <phone>+ 45 56 51 31 17</phone>
    <email>laml@regionsjaelland.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Dep. Radiation Oncology, Zealand University Hospital</name>
      <address>
        <city>Næstved</city>
        <state>Sjaelland</state>
        <zip>DK-4700</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Redas Trepiakas</last_name>
      <phone>+4556513231</phone>
      <phone_ext>+4556513231</phone_ext>
      <email>rtr@regionsjaelland.dk</email>
    </contact>
    <contact_backup>
      <last_name>K F E</last_name>
      <phone>+ 45 56 51 31 17</phone>
      <email>laml@regionsjaelland.dk</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University Hospital Schleswig-Holstein</name>
      <address>
        <city>Kiel</city>
        <state>Schleswig-Holstein</state>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Juergen Dunst, MD</last_name>
      <phone>0049 431 500-26500</phone>
      <email>juergen.dunst@uksh.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Schleswig-Holstein</name>
      <address>
        <city>Lubeck</city>
        <state>Schleswig-Holstein</state>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dirk Rades, MD</last_name>
      <phone>0049 451-500-45400</phone>
      <email>dirk.rades@uksh.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>July 30, 2018</study_first_submitted>
  <study_first_submitted_qc>September 3, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 5, 2018</study_first_posted>
  <last_update_submitted>September 10, 2018</last_update_submitted>
  <last_update_submitted_qc>September 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Defined in Partner Agreement Contract</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>1. august 2018</ipd_time_frame>
    <ipd_access_criteria>Innocan Partners</ipd_access_criteria>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 1, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/34/NCT03658434/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

